News >

Brufsky Highlights Novel Approaches for TNBC

Kristi Rosa
Published: Wednesday, Nov 21, 2018

Adam M. Brufsky, MD, PhD

Adam M. Brufsky, MD, PhD
As investigators increase their understanding of the biology of triple-negative breast cancer (TNBC), new approaches are emerging that could optimize patient outcomes.

State of the Science Summit™ on Breast Cancer, Brufsky, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, highlighted novel treatment approaches being explored in the TNBC space.

OncLive: Could you provide an overview of your presentation on treatment approaches in TNBC?

Brufsky: What I talked about today had to do mostly with the genomic assays for breast cancer—in particular, the 21-Gene recurrence score assay, which is Oncotype DX, and the 70-gene signature test, which is MammaPrint. I compared and contrasted 2 of the large randomized clinical trials that have been done—TAILORx for Oncotype DX and MINDACT for MammaPrint.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication